processing....
This pathophysiological hypothesis might enable improved management of patients in the acute phase of stress cardiomyopathy. Whereas some patients require only supportive therapy, others can present with acute cardiogenic shock, necessitating admission to intensive care for hemodynamic support. Epinephrine has a causative role in stress cardiomyopathy and the deterioration of myocardial function, and additional 'therapeutic' epinephrine might drive further β2AR–Gi-protein-mediated negative inotropism. The use of inotropic agents, particularly dobutamine, in patients with stress cardiomyopathy and cardiogenic shock, therefore, seems counterintuitive. Some β-blockers can also cause stimulus trafficking of β2ARs to Gi protein coupling,[64] which suggests that use of these agents in patients with stress cardiomyopathy might be inappropriate, despite the high catecholamine levels. Aortic balloon pump counterpulsation might be the best first-line hemodynamic support, with intravenous calcium or levosimendan, the calcium- sensitizing agent, as second-line pharmacological support. In cases of life-threatening acute left ventricular failure, temporary mechanical support with a left ventricular assist device can be indicated. Ventricular support could provide time for the ventricular myocardium to recover, as observed in the natural history of stress cardiomyopathy. We must highlight, however, that these proposals are founded on a hypothesis and require a clinical study for validation.